GlassScriptPhysician profile
Matthew T Bobzien
NPI 1962508812
$11,332.07
in general payments reported to CMS, 2019-2025
63 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $1,057 · 2021: $1,656 · 2022: $1,126 · 2023: $1,629 · 2024: $1,774 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,241.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,240.02 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,177.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $998.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $787.13 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $699.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $607.88 | 2019-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $598.89 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $409.96 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $310.55 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $257.64 | 2019-2024 | Rexulti |
| Glaxosmithkline, LLC. | $256.75 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.85 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $189.04 | 2019-2023 | |
| Allergan, INC. | $182.88 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.57 | 2019-2023 | Xifaxan |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bobzien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.